sbli-ant3310 A novel combination treatment effective against all multidrug-resistant pathogens deemed as a critical priority by the WHO
- Coordinator
- Antabio, France
- Runs
- 1 February 2023 to 31 December 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €5.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190159682
What the project is doing
In the project's own words, from its summary on CORDIS.
Antimicrobial resistance (AMR) due to multidrug-resistant Gram-negative bacteria are an increasingly serious healthcare threat, exacerbated by major economic issues underlying the development of new antibacterial drugs. The effectiveness of β-lactam antibiotics, the most important class of antibacterial agents, is impaired by the production of β-lactamase enzymes by drug-resistant bacteria. We are developing a combination of a well-known antibiotic (meropenem) and ANT3310, our proprietary, best-in-class serine-β-lactamase inhibitor, intended for the treatment of hospital-acquired infections caused by drug-resistant pathogens.
Our treatment has been pre-clinically proven to be efficacious against all three pathogens deemed a critical priority by the World Health Organization (WHO). We will conduct three clinical trials and next out-license ANT3310 to a pharmaceutical partner. We expect market approval by 2029 and that ANT3310 will generate over €10bn in sales within 13 years.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Antabio | Labege | France | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI